Last updated: July 31, 2026
Xibrom, the former brand name for bromfenac ophthalmic solution 0.09%, is no longer an active commercial growth product. The FDA approved Xibrom for the treatment of postoperative ocular inflammation and reduction of ocular pain in patients undergoing cataract surgery. ISTA Pharmaceuticals launched the product, later transitioning the bromfenac franchise to once-daily formulations including Bromday and Prolensa. Current commercial activity is concentrated in generic bromfenac ophthalmic products rather than Xibrom itself.[1][2]
No active late-stage clinical-development program is associated with the Xibrom brand. Bromfenac remains clinically relevant as an ophthalmic nonsteroidal anti-inflammatory drug, but its development profile is mature, its branded exclusivity has expired, and generic competition limits revenue potential.
What is Xibrom and what was it approved to treat?
Xibrom is bromfenac ophthalmic solution 0.09%, a topical NSAID administered to the eye after cataract surgery.
| Attribute |
Xibrom |
| Active ingredient |
Bromfenac sodium sesquihydrate |
| Dosage form |
Ophthalmic solution |
| Strength |
0.09% |
| Original sponsor |
ISTA Pharmaceuticals Inc. |
| FDA application |
NDA 21-664 |
| FDA approval |
2005 |
| Primary indication |
Treatment of postoperative ocular inflammation and reduction of ocular pain after cataract surgery |
| Therapeutic class |
Ophthalmic nonsteroidal anti-inflammatory |
| Current branded status |
Discontinued as an active commercial brand |
| Current competitive products |
Generic bromfenac ophthalmic solution; later branded bromfenac products |
Xibrom was administered twice daily in the original product labeling. The product competed with ophthalmic NSAIDs such as ketorolac and nepafenac, as well as corticosteroid products used in postoperative ophthalmic care.[1]
What is the current clinical-trial status of Xibrom?
Xibrom has no meaningful current clinical-development pipeline. Its pivotal development program was completed before FDA approval, and the product is not being advanced as a new molecular entity, biologic, or novel delivery platform.
Historical clinical studies evaluated bromfenac for:
- Reduction of ocular pain after cataract surgery
- Reduction of anterior chamber inflammation
- Comparison with placebo or vehicle
- Comparison with other postoperative ophthalmic anti-inflammatory regimens
- Duration of dosing and convenience of administration
- Safety outcomes, including corneal complications and delayed healing
The clinical evidence supporting approval established bromfenac's activity in postoperative inflammation and pain. The product's clinical-development risk is therefore low from an efficacy-validation perspective, but the commercial opportunity is also limited because the relevant indication is established and generic alternatives are available.
Are there active Xibrom clinical trials?
No active trial program is associated with the discontinued Xibrom brand. ClinicalTrials.gov records may include historical studies involving bromfenac or postoperative cataract treatment, but those records do not indicate a current branded Xibrom development strategy.[3]
Future studies involving bromfenac are more likely to examine:
- Combination therapy with corticosteroids
- Alternative ophthalmic delivery systems
- Reduced-frequency dosing
- Comparative postoperative regimens
- Use in refractive surgery or other anterior-segment procedures
Those studies would concern the active ingredient or a new formulation, not the original Xibrom product.
When did Xibrom lose exclusivity?
Xibrom's principal commercial protection has expired. The product was approved in 2005, and generic bromfenac ophthalmic products subsequently entered the U.S. market. The original Xibrom brand no longer has the exclusivity profile of a protected specialty ophthalmic product.
FDA exclusivity and patent protection are separate concepts. Regulatory exclusivity may block approval of a competing application for a defined period, while patents may protect the active ingredient, formulation, manufacturing process, or method of use. For Xibrom, the practical loss of commercial exclusivity is reflected by the availability of generic bromfenac ophthalmic solution.
What patents protected Xibrom?
Xibrom's historical protection involved bromfenac-related composition, formulation, and ophthalmic-use rights. The relevant patent portfolio was linked to bromfenac ophthalmic formulations and postoperative use rather than to a novel biological mechanism.
A current commercial freedom-to-operate review should distinguish among:
- Patents listed in the FDA Orange Book for the original NDA.
- Expired patents covering bromfenac or its ophthalmic formulation.
- Later patents covering once-daily dosing or alternative formulations.
- Patents assigned or licensed to ISTA, Bausch + Lomb, Senju, or other ophthalmic companies.
- Formulation patents that may remain relevant outside the United States.
The FDA Orange Book is the controlling source for active patent listings associated with approved drug applications. Because Xibrom is discontinued and its historic patents are no longer the primary market barrier, current generic entry risk is high.[4]
What is the Orange Book status of Xibrom?
Xibrom was associated with FDA New Drug Application 21-664. The product's Orange Book relevance is historical rather than commercially protective. An NDA may remain in FDA records even after the associated product is discontinued, while listed patents may expire or cease to block generic approval.
The Orange Book should be reviewed for:
- NDA 21-664
- Patent expiration dates
- Patent delisting or expiration status
- Therapeutic-equivalence ratings for generic bromfenac products
- Related bromfenac NDAs and supplemental applications
The existence of an historic NDA does not prevent generic competition. Generic applicants can rely on the reference product's safety and efficacy data through an abbreviated new drug application, subject to applicable patent certifications and FDA requirements.[4][5]
What generic entry risks exist for Xibrom?
Generic entry risk is high because bromfenac is a mature small-molecule ophthalmic product with an established FDA approval pathway.
A generic applicant can generally pursue approval through an ANDA by demonstrating pharmaceutical equivalence and bioequivalence or other applicable requirements. The principal technical requirements include:
- Matching active ingredient and strength
- Equivalent dosage form
- Appropriate ophthalmic quality standards
- Sterility
- Container-closure integrity
- Stability
- Comparable inactive-ingredient profile or adequate justification
- Manufacturing controls for ophthalmic products
For a topical ophthalmic solution, manufacturing and quality controls remain important, but they generally do not create the level of barrier associated with complex biologics, depot injectables, or device-integrated delivery systems.
What Paragraph IV challenges affected Xibrom?
Historical Paragraph IV activity may have been relevant to bromfenac ANDAs during the period when listed patents remained enforceable. That period has largely passed. Current Paragraph IV risk is therefore not a major commercial issue for the discontinued Xibrom brand.
The relevant competitive issue is generic substitution, not a new wave of branded patent litigation. Generic applicants may still use Paragraph IV certifications against patents listed for related bromfenac products if those patents remain active, but the original Xibrom franchise no longer represents a high-value litigation target.
What formulations are protected by bromfenac patents?
Bromfenac intellectual property historically focused on ophthalmic solutions and dosing regimens. Formulation protection can cover:
- Bromfenac concentration
- Salt form
- pH range
- Solubilizing agents
- Preservatives
- Surfactants
- Viscosity modifiers
- Reduced-frequency dosing
- Treatment duration
- Postoperative administration
Later products such as Bromday and Prolensa were commercially differentiated through formulation and dosing convenience. Once-daily dosing reduced administration burden compared with twice-daily Xibrom and helped extend the commercial life of the bromfenac franchise.
The strongest residual IP opportunities would involve a clearly differentiated delivery system, such as preservative-free packaging, sustained release, improved corneal penetration, or a combination product. A conventional bromfenac solution has limited patent strength when the formulation and clinical use are already established.
How strong is the Xibrom patent estate?
The original Xibrom patent estate is commercially weak today because:
- The product is no longer an active branded growth asset.
- Generic bromfenac products are available.
- The main therapeutic use is established.
- Historic patent protection has expired or lost practical exclusivity.
- Ophthalmic solution manufacturing is technically manageable for experienced generic manufacturers.
- Later bromfenac products have their own regulatory and patent histories.
| Patent-estate factor |
Current assessment |
| Active-ingredient protection |
Weak or expired |
| Original formulation protection |
Weak or expired |
| Method-of-use protection |
Limited practical value |
| Once-daily formulation protection |
More relevant to later bromfenac brands |
| Manufacturing barrier |
Moderate for sterile ophthalmic production |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Litigation risk |
Low for the discontinued Xibrom brand |
| Licensing value |
Low unless tied to a differentiated delivery platform |
What is the FDA regulatory status of Xibrom?
Xibrom was FDA-approved, but the brand is discontinued. FDA approval of the active ingredient and the continued presence of generic bromfenac products are separate from the commercial status of the Xibrom label.
The FDA regulatory pathway for a new bromfenac product depends on the development strategy:
- A conventional generic solution would generally use an ANDA.
- A materially different formulation may require a 505(b)(2) application.
- A combination product could require additional clinical and regulatory support.
- A new delivery device could trigger drug-device combination-product requirements.
A new sponsor would need a commercially meaningful differentiation strategy to justify a full development program.
Which companies compete with Xibrom or bromfenac?
Xibrom's original commercial competitors included other ophthalmic NSAIDs and corticosteroid products.
| Product or class |
Active ingredient |
Commercial relationship |
| Xibrom |
Bromfenac |
Original twice-daily bromfenac brand |
| Bromday |
Bromfenac |
Later once-daily bromfenac brand |
| Prolensa |
Bromfenac |
Later bromfenac formulation and dosing franchise |
| Acular and generics |
Ketorolac |
Established ophthalmic NSAID competitor |
| Nevanac and generics |
Nepafenac |
Ophthalmic NSAID competitor |
| Pred Forte and generics |
Prednisolone acetate |
Corticosteroid alternative |
| Durezol and generics |
Difluprednate |
Potent corticosteroid alternative |
The competitive market is driven by ophthalmologist prescribing, formulary access, generic pricing, cataract-surgery volume, and bundled postoperative treatment protocols.
What is the market size and revenue outlook for Xibrom?
Xibrom has no meaningful standalone revenue-growth outlook because the branded product has been discontinued. Public company reporting does not support a current independent revenue projection for Xibrom.
The relevant market is generic bromfenac and the broader postoperative ophthalmic anti-inflammatory segment. Its growth is linked mainly to:
- Global cataract-procedure volume
- Aging populations
- Refractive and lens-replacement procedures
- Generic price erosion
- Prescribing substitution
- Payer and pharmacy economics
A commercial forecast for the Xibrom brand should be modeled as follows:
| Forecast period |
Xibrom branded outlook |
| Near term |
Negligible branded revenue |
| Medium term |
No credible branded recovery absent relaunch |
| Long term |
Limited value as a standalone brand |
| Generic bromfenac market |
Stable procedure-linked demand with pricing pressure |
| New differentiated formulation |
Potentially investable if protected by new IP and clinical benefit |
The most valuable opportunity is not relaunching Xibrom as a conventional solution. It would be developing a differentiated bromfenac product with stronger adherence, tolerability, preservative reduction, or delivery technology.
What patent litigation affects Xibrom?
No major current litigation involving the discontinued Xibrom brand has a material effect on the market outlook. Historical disputes may have involved generic entry, Orange Book patents, or later bromfenac formulations, but those disputes do not create a current barrier comparable to litigation around high-value biologics or protected specialty drugs.
A current diligence review should separate:
- Litigation involving NDA 21-664
- Litigation involving Bromday or Prolensa
- Litigation involving generic bromfenac manufacturers
- Patent disputes over formulation or dosing
- Settlement agreements affecting generic launch dates
Settlements involving later bromfenac products would not automatically apply to Xibrom.
What licensing deals affected the Xibrom franchise?
ISTA Pharmaceuticals developed and commercialized Xibrom before its ophthalmology assets were acquired by Bausch + Lomb. The acquisition transferred important ophthalmic commercial assets and products, including the bromfenac franchise, into Bausch + Lomb's portfolio.[6]
The commercial significance of the transaction was greater for the broader ophthalmic portfolio than for Xibrom alone. Licensing or acquisition value today would depend on rights to a new formulation, manufacturing platform, or combination product rather than on the discontinued Xibrom brand.
Is biosimilar risk relevant to Xibrom?
No. Biosimilars apply to biological products. Bromfenac is a chemically synthesized small molecule, so its competitive threat comes from generic drugs, not biosimilars.
The relevant regulatory concepts are ANDA approval, therapeutic equivalence, patent certification, and generic substitution.
What are the likely launch scenarios for a new bromfenac product?
Conventional generic launch
This is the lowest-risk regulatory pathway and the least attractive commercial opportunity. Multiple generic manufacturers can compete on price, supply reliability, and pharmacy contracting.
Branded relaunch of Xibrom
This scenario has low probability of commercial success without new clinical differentiation. The original twice-daily product lacks a clear advantage over generic bromfenac and later once-daily products.
505(b)(2) reformulation
A reformulated product could support premium pricing if it demonstrates improved dosing convenience, ocular tolerability, preservative-free use, or delivery performance. Patent protection would be central to the investment case.
Combination product
Bromfenac combined with a corticosteroid or another postoperative agent could reduce the number of products used after surgery. The product would face clinical, regulatory, manufacturing, and patent complexity.
How does Xibrom compare with Prolensa and generic bromfenac?
| Factor |
Xibrom |
Prolensa |
Generic bromfenac |
| Dosing history |
Twice daily |
Once daily |
Depends on product label |
| Brand status |
Discontinued |
Later branded franchise |
Commercially available |
| Patent value |
Largely historical |
More relevant historically |
Limited product-specific protection |
| Price position |
No current branded role |
Premium branded positioning |
Low-cost |
| Clinical differentiation |
Limited today |
Dosing convenience |
Price and access |
| Generic-entry risk |
Realized |
High as patents expire |
Existing competitive condition |
| Investment outlook |
Low |
Dependent on current commercial rights |
Volume-driven, margin constrained |
Key Takeaways
- Xibrom is bromfenac ophthalmic solution 0.09%, originally approved by the FDA in 2005.
- The product is discontinued as an active branded commercial asset.
- No current Xibrom clinical-development program has meaningful commercial significance.
- Generic bromfenac products have replaced the original brand in the U.S. market.
- Xibrom's historic patent estate has limited present-day blocking value.
- Biosimilar risk does not apply because bromfenac is a small molecule.
- A conventional Xibrom relaunch would have low commercial attractiveness.
- The investable opportunity lies in differentiated bromfenac delivery, combination therapy, or preservative-free formulations.
- Standalone Xibrom revenue should be projected at negligible levels; the broader bromfenac market is procedure-linked and exposed to generic price erosion.
FAQs About Xibrom Patent and Market Status
Is Xibrom still available in the United States?
The original Xibrom brand is discontinued. Bromfenac ophthalmic products remain available through generic and later branded formulations.
Is Xibrom the same as Prolensa?
Both contain bromfenac, but they are different branded products with different formulation and dosing histories. Prolensa was developed as a later bromfenac product with once-daily dosing.
Can a generic company still launch bromfenac ophthalmic solution?
Yes. Generic bromfenac ophthalmic products are already present in the market, subject to FDA approval, applicable patent certifications, and manufacturing requirements.
Does Xibrom have biologic or biosimilar competition?
No. Bromfenac is a small-molecule drug. Its competition is from generic drugs rather than biosimilars.
What would make a new bromfenac product commercially attractive?
A new product would need defensible differentiation, such as once-daily or less frequent dosing, preservative-free delivery, improved ocular tolerability, sustained release, or a combination regimen supported by patents and clinical data.
References
-
U.S. Food and Drug Administration. (2005). Xibrom (bromfenac ophthalmic solution) prescribing information. FDA.
-
Bausch + Lomb. (n.d.). Bromfenac ophthalmic products and prescribing information. Bausch + Lomb.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov search results for bromfenac ophthalmic and postoperative ocular inflammation. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. FDA.
-
Bausch & Lomb Incorporated. (2012). Acquisition of ISTA Pharmaceuticals, Inc. Company transaction materials.
